

TABLE OF COMMITMENTS

▶ Monday,
30 January 2012
London

- ▶ On 30 January 2012, a range of public and private partners are announcing a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by 2020 in support of the World Health Organization's NTD goals. The announcement includes contributions from pharmaceutical companies, development agencies, endemic countries, research organisations and the Bill & Melinda Gates Foundation. These commitments were accompanied by a joint London Declaration on NTDs, in which partners pledged new levels of collaboration and tracking and reporting of progress. Taken as a whole, this is the largest coordinated action to address NTDs to date.

Listed below are new commitments to combat NTDs, as well as previously existing drug donation programs that will continue through 2020. These commitments build on decades of work by these organisations to tackle NTDs, and include contributions to sustain, expand and extend drug supply, accelerate R&D for new treatments, and increase funding to improve drug delivery and implementation programs. Full details are outlined below.

Disease(s)	Need	Commitment(s)	Contributor(s)
Multiple	Clear, coordinated goals for NTD control and elimination programs	Launch of 2020 Roadmap for Implementation with disease-specific goals and strategies for control and elimination	World Health Organization
	Funding and development of various NTD Initiatives	£195 million through 2015, targeted at Guinea worm, lymphatic filariasis, river blindness and schistosomiasis, as well as the development of new programmes for blinding trachoma, visceral leishmaniasis, research and integrated country approaches	UK Department for International Development (DFID)
		Building on its US\$212 million investment since 2006, USAID will continue support to over 20 countries to introduce and/or scale up integrated NTD programs, including three new countries: Mozambique, Senegal and Cambodia. The U.S. Congress appropriated \$89 million to USAID for NTD control in FY2012.	U.S. Agency for International Development (USAID)
		US\$5 million to selected sites in the Americas and Africa to expand work in NTD control and program enhancement	Mundo Sano

▶ Partners



TABLE OF COMMITMENTS

► Monday,
30 January 2012
London

Disease(s)	Need	Commitment(s)	Contributor(s)
Multiple <i>(continued)</i>	Funding and development of various NTD Initiatives <i>(continued)</i>	US\$363 million over five years to overcome barriers to success and address critical gaps to achieve the control and elimination of targeted NTDs by 2020	Bill & Melinda Gates Foundation
		At the country level, extend its financing and technical support to help countries build stronger community health systems that will integrate NTD elimination and control. At the regional level, the World Bank will continue fiduciary oversight of the existing trust fund that supports the fight against river blindness in Africa, and will also work with other partners to expand the trust fund to eliminate or control preventable NTDs on the continent.	World Bank
	Program implementation in NTD-endemic countries	Implementation of coordinated plan to control and eliminate NTDs, guided by WHO recommendations adapted to the local setting	Brazil
		Implementation of a fully integrated, multisectoral plan to control and eliminate NTDs, guided by WHO recommendations adapted to the local setting <ul style="list-style-type: none"> - Reach full geographic coverage of all endemic areas for lymphatic filariasis, soil-transmitted helminthes and schistosomiasis - Completely map and reach full geographic coverage of trachoma by 2018 - Build capacity for surveillance and action to sustain gains from mass drug administration programs 	Mozambique
		Implementation of a fully integrated plan to control and eliminate NTDs, guided by WHO recommendations adapted to the local setting	Tanzania
		Implementation of a fully integrated plan to control and eliminate NTDs, guided by WHO recommendations adapted to the local setting	Bangladesh

► Partners



TABLE OF COMMITMENTS

► Monday,
30 January 2012
London

Disease(s)	Need	Commitment(s)	Contributor(s)
Multiple <i>(continued)</i>	Additional tools	Consideration of use of ivermectin for other diseases	MSD
		Access to selected substances to third parties, including DNDi, out of its compound libraries to find new treatments for NTDs	Bayer
		Access to selected proprietary compound libraries to third parties, including DNDi, to develop new medicines for certain NTDs	Bristol-Myers Squibb
		Donate azithromycin to a study on the potential for the drug to reduce mortality in young children.	Pfizer
Blinding Trachoma	Drug supply through 2020	Continued donation of azithromycin for blinding trachoma until at least 2020	Pfizer
	Funding for program implementation	Donation of \$6.9 million for trachoma elimination in China	Lions Clubs International Foundation
Chagas Disease	Drug supply through 2020	Doubling of existing donation of nifurtimox to 1 million tablets/year through 2020	Bayer
	Additional tools	Partnership with DNDi to provide targeted access to proprietary compound libraries to develop new medicines	Abbott, AstraZeneca, Eisai, Novartis and Pfizer (GlaxoSmithKline, MSD and Sanofi also partner)
Guinea Worm Disease	Funding for program implementation	Filled funding gap through the following contributions: - DFID (£20 million) (announced 21 January) - Bill & Melinda Gates Foundation (\$23.3 million) - United Arab Emirates (\$10 million) - Children's Investment Fund Foundation (\$6.7 million)	DFID Bill & Melinda Gates Foundation United Arab Emirates Children's Investment Fund Foundation

► Partners



TABLE OF COMMITMENTS

► Monday,
30 January 2012
London

Disease(s)	Need	Commitment(s)	Contributor(s)
Leprosy	Drug supply through 2020	Extension of existing donation of rifampicin, clofazimine and dapsone in quantities requested by WHO to 2020	Novartis
	Comprehensive approach for implementation	Organization of multi-stakeholder initiative to intensify leprosy control efforts in a final push against the disease	Novartis
Lymphatic Filariasis	Drug supply through 2020	Sanofi, Eisai and the Bill & Melinda Gates Foundation will work together to provide 120 million DEC tablets to the WHO for its Global Lymphatic Filariasis Elimination programme. Combined with Eisai's donation commitment that will start in 2014, these new tablets will ensure a sufficient supply of DEC from 2012 through 2020.	Sanofi, Eisai and the Bill & Melinda Gates Foundation
		Donation of 2.2 billion tablets of DEC from 2014 through 2020	Eisai
		Continuation of existing donation of 600 million tablets/year of albendazole (unlimited duration)	GlaxoSmithKline
		Continuation of existing unlimited donation of ivermectin (where co-endemic with onchocerciasis) (unlimited duration)	MSD
Lymphatic Filariasis & River Blindness (Onchocerciasis)	New macrofilaricide to kill adult form of worms (existing drugs do not kill adult worms, requiring repetitive treatments)	Partnerships under the coordination of DNDi to repurpose flubendazole as a potential macrofilaricide to combat lymphatic filariasis and river blindness: -Abbott is conducting initial drug reformulation studies and providing scientific expertise for preclinical development, with technical and supply assistance from Johnson & Johnson -If pre-clinical development is successful, Johnson & Johnson will co-fund clinical development, and collaborate with other partners, including technical support from Pfizer's staff scientists. Johnson & Johnson would obtain regulatory approval.	Abbott, Johnson & Johnson and Pfizer

► Partners



TABLE OF COMMITMENTS

► Monday,
30 January 2012
London

Disease(s)	Need	Commitment(s)	Contributor(s)
Lymphatic Filariasis & River Blindness (Onchocerciasis) <i>(continued)</i>	New macrofilaricide to kill adult form of worms (existing drugs do not kill adult worms, requiring repetitive treatments) <i>(continued)</i>	Partnership with DNDi to provide targeted access to proprietary compound libraries to develop a macrofilaricide to combat lymphatic filariasis and river blindness	AstraZeneca, Johnson & Johnson, Novartis and Sanofi
River Blindness (Onchocerciasis)	Drug supply through 2020	Continuation of unlimited donation of ivermectin (unlimited duration)	MSD
Schistosomiasis	Drug supply through 2020	Significant increase in annual donation level of praziquantel tablets from 25 million to 250 million tablets/year, extending the program indefinitely	Merck KGaA
		Development of a child friendly formulation of praziquantel	Merck KGaA
	Additional awareness of control programmes	Financial support of a WHO-led school awareness programme for schistosomiasis	Merck KGaA
Sleeping Sickness (Human African Trypanosomiasis)	Drug supply through 2020	Extension of existing donation of eflornithine, melarsoprol and pentamidine to 2020, and logistical support to ensure that the drugs continue to reach patients at point of care cost-free	Sanofi
		Extension of existing donation of suramin and nifurtimox to 2020	Bayer
	Additional tools	Partnership with DNDi to provide targeted access to proprietary compound libraries to develop new medicines	Abbott, AstraZeneca, Novartis and Pfizer (GlaxoSmithKline, MSD and Sanofi already partner)

► Partners

- 5 -



TABLE OF COMMITMENTS

► Monday,
30 January 2012
London

Disease(s)	Need	Commitment(s)	Contributor(s)
Sleeping Sickness (Human African Trypanosomiasis) <i>(continued)</i>	Additional tools <i>(continued)</i>	Partnership with DNDi to co-develop a new oral drug candidate for sleeping sickness, oxaborole/SCYX-7158, in addition to fexinidazole, which is already in clinical development	Sanofi
Soil-Transmitted Helminthes	Drug supply through 2020	Extension of existing albendazole donation of 400 million tablets/year to 2020	GlaxoSmithKline
		Extension of existing mebendazole donation of 200 million tablets/year to 2020	Johnson & Johnson
Visceral Leishmaniasis	Additional tools	Partnership with DNDi to provide targeted access to proprietary compound libraries to develop new medicines	Abbott, AstraZeneca, Eisai, Novartis and Pfizer (Sanofi, GlaxoSmithKline and MSD already partner)
		Partnership with DNDi to develop ravuconazole, a new oral drug currently in trials for Chagas disease, as a new treatment for cutaneous leishmaniasis	Eisai
	Drug supply	Donation of AmBisome for 50,000 patients in South Asia and East Africa from 2012-2017; continuation of program to offer VL at cost and commitment to investigate and invest in technologies and processes that could reduce the cost of AmBisome in resource-limited countries	Gilead
	Training for health care providers	Development of new training tools for leishmaniasis for health care providers and patients	Sanofi

► Partners

- 6 -

